{"doi":"10.1007/s12032-012-0434-2","title":"Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience","abstract":null,"journal":"Medical Oncology","year":2013,"id":662707,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1730141,"name":"Pierluigi Bonomo","orcid":null,"position":1,"is_corresponding":false},{"id":1564083,"name":"Icro Meattini","orcid":null,"position":2,"is_corresponding":false},{"id":1645637,"name":"Gabriele Simontacchi","orcid":null,"position":3,"is_corresponding":false},{"id":1730142,"name":"Daniela Greto","orcid":null,"position":4,"is_corresponding":false},{"id":1593919,"name":"Isacco Desideri","orcid":"0000-0002-9880-8387","position":5,"is_corresponding":false},{"id":1730143,"name":"Fiammetta Meacci","orcid":null,"position":6,"is_corresponding":false},{"id":1564449,"name":"Vieri Scotti","orcid":null,"position":7,"is_corresponding":false},{"id":1730144,"name":"Sara Cecchini","orcid":null,"position":8,"is_corresponding":false},{"id":1730145,"name":"Jacopo Nori","orcid":null,"position":9,"is_corresponding":false},{"id":1730146,"name":"Luis Jose Sanchez","orcid":null,"position":10,"is_corresponding":false},{"id":1730147,"name":"Lorenzo Orzalesi","orcid":null,"position":11,"is_corresponding":false},{"id":1582315,"name":"Fabiola Paiar","orcid":null,"position":12,"is_corresponding":false},{"id":1730148,"name":"Gianpaolo Biti","orcid":null,"position":13,"is_corresponding":false},{"id":1564133,"name":"Lorenzo Livi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience","abstract":"The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m(2) on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6-44.8 months), progression-free survival was 8.1 months (range 2.3-33.2 months), and time to treatment failure was 8.4 months (range 2.3-33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23283649","pmcid":null,"openalex_id":"https://openalex.org/W2165278624","authors":[],"funders":[],"total_grants":0,"fwci":0.7217,"citation_percentile":0.71465075,"influential_citations":0,"citation_trend":[{"year":2013,"count":3},{"year":2015,"count":1},{"year":2016,"count":1},{"year":2017,"count":1},{"year":2019,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://link.springer.com/content/pdf/10.1007/s12032-012-0434-2.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1007/s12032-012-0434-2/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/s12032-012-0434-2","host_type":"publisher"},{"url":"https://doi.org/10.1007/s12032-012-0434-2","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23283649","host_type":"repository"},{"url":"http://hdl.handle.net/11568/840792","host_type":"repository"},{"url":"http://hdl.handle.net/2158/822153","host_type":"repository"}],"fields_of_study":["Cancer Treatment and Pharmacology","HER2/EGFR in Cancer Research","Colorectal Cancer Treatments and Studies","Adult","Aged","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Breast Neoplasms","Disease-Free Survival","Female","Humans","Middle Aged","Neoplasm Grading","Neoplasm Staging","Paclitaxel","Erb-b2 Receptor Tyrosine Kinases","Treatment Outcome"],"mesh_terms":["Bevacizumab","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms","Female","Humans","Middle Aged","Neoplasm Staging","Treatment Outcome","Paclitaxel","Disease-Free Survival","Erb-b2 Receptor Tyrosine Kinases","Receptor, ErbB-2","Neoplasm Grading","Antibodies, Monoclonal, Humanized"],"keywords":["Bevacizumab","Medicine","Metastatic breast cancer","Paclitaxel","Regimen","Internal medicine","Oncology","Toxicity","Breast cancer","Surgery","Cancer","Chemotherapy","Gastroenterology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T17:02:27.236196Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}